Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $1.5 million.

  • Harvard Bioscience's Other Non-Current Liabilities fell 253.16% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 253.16%. This contributed to the annual value of $1.3 million for FY2024, which is 1497.29% down from last year.
  • Latest data reveals that Harvard Bioscience reported Other Non-Current Liabilities of $1.5 million as of Q3 2025, which was down 253.16% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Other Non-Current Liabilities ranged from a high of $2.8 million in Q1 2021 and a low of $418000.0 during Q2 2022
  • For the 5-year period, Harvard Bioscience's Other Non-Current Liabilities averaged around $1.4 million, with its median value being $1.4 million (2025).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 23039.44% in 2021, then crashed by 8353.03% in 2022.
  • Harvard Bioscience's Other Non-Current Liabilities (Quarter) stood at $486000.0 in 2021, then skyrocketed by 107.0% to $1.0 million in 2022, then surged by 46.72% to $1.5 million in 2023, then decreased by 14.97% to $1.3 million in 2024, then rose by 16.57% to $1.5 million in 2025.
  • Its Other Non-Current Liabilities was $1.5 million in Q3 2025, compared to $1.4 million in Q2 2025 and $1.4 million in Q1 2025.